Clinical trials: Acute EBV Hepatitis
Acute Hepatitis A, Acute Hepatitis B
Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis
The purpose of this study is to assess whether two higher doses (280mg or 420mg three times daily)of silymarin therapy are safe and tolerable, and shorten the illness in patients with acute viral hepatitis compared to placebo.
- Conditions
- Acute Hepatitis A, Acute Hepatitis B, Acute Hepatitis C, Acute Hepatitis E
- Trial name
- NCT00755950
- Testing
- Silymarin, Lactose monohydrate
- Where
- 3 sites in Egypt
- Volunteers
- 70 people
- Sponsor
- University of Maryland, Baltimore